

GENERAL ANNOUNCEMENT::RESULTS BRIEFING 1Q2020

Issuer & Securities

Issuer/ Manager

HYPHENS PHARMA INTERNATIONAL LIMITED

Securities

HYPHENS PHARMA INTL LIMITED - SG1EE4000006 - 1J5

Stapled Security

No

Announcement Details

Announcement Title

General Announcement

Date & Time of Broadcast

14-May-2020 12:14:48

Status

New

Announcement Sub Title

RESULTS BRIEFING 1Q2020

Announcement Reference

SG200514OTHRJ3DB

Submitted By (Co./ Ind. Name)

Lim See Wah

Designation

Executive Chairman and Chief Executive Officer

Description (Please provide a detailed description of the event in the box below)

Please refer to the attached.

This announcement has been prepared by the Company and its contents have been reviewed by the Sponsor, DBS Bank Ltd. ("Sponsor") for compliance with the Singapore Exchange Securities Trading Limited ("SGX-ST") Listing Manual Section B: Rules of Catalyst. The Sponsor has not verified the contents of this announcement.

This announcement has not been examined or approved by the SGX-ST. The SGX-ST assumes no responsibility for the contents of this announcement including the accuracy, completeness or correctness of any of the information, statements or opinions made or reports contained in this announcement.

The contact persons for the Sponsor are Ms Heng Mui Mui, Managing Director, and Mr Kelvin Wong, Senior Vice President, who can be contacted at 12 Marina Boulevard, Level 46, Marina Bay Financial Centre Tower 3, Singapore 018982, Telephone: +65 6878 8888.

Attachments

[Hyphens%20Results%20Briefing%20-%201Q2020.pdf](#)

Total size =2348K MB

GOING DIGITAL

Introducing brand new Ceradan website www.ceradan.com



Singapore's Leading Specialty Pharmaceutical and Consumer Healthcare Group



GOING DIGITAL

Revamped Virtual Hypermart www.pom.com.sg



Singapore's Leading Specialty Pharmaceutical and Consumer Healthcare Group



INVESTING FOR GROWTH

- 1 **Establishing a broader geographical footprint**
 - Cementing leadership position in Singapore and deepening presence in ASEAN
 - Expanding international footprint in Asia, Middle East and Africa
- 2 **Investment in proprietary brands**
 - Driving growth of skin health portfolio through Ceradan® and TDF® brands
 - Nurturing Ocean Health® as a leading nutritional supplement brand of Singapore
 - R&D for new products, improve formulation & generate scientific validation



Singapore's Leading Specialty Pharmaceutical and Consumer Healthcare Group



INVESTING FOR GROWTH

- 3 **Strengthening specialty pharma portfolio**
 - Launching new specialty pharma products in regional markets
 - Seeking licensing opportunities for new products
- 4 **Reinforcing medical hypermart and digital segment**
 - Continue to leverage its broad network in the Singapore market
 - Exploring new digital business initiatives
- 5 **Acquisitions**
 - Continue to source for synergistic opportunities




Singapore's Leading Specialty Pharmaceutical and Consumer Healthcare Group



FINANCIAL HIGHLIGHTS




Singapore's Leading Specialty Pharmaceutical and Consumer Healthcare Group




1.2 SEGMENT REVENUE

Business Segments





1Q2020



1Q2019



Geography



Singapore's Leading Specialty Pharmaceutical and Consumer Healthcare Group



2 IMPROVING MARGINS



Singapore's Leading Specialty Pharmaceutical and Consumer Healthcare Group



3 STRONG FINANCIAL POSITION & CASH FLOW

S\$'000	31 Mar 2020	31 Dec 2019
Total assets	84,031	80,131
Cash & cash equivalents	27,799	26,165
Total liabilities	37,894	36,055
Financial liabilities	720	300
Total equity	46,137	44,076
NAV per share (cents)	15.36	14.67

S\$'000	1Q2020	1Q2019
Cashflow from operating activities	2,025	2,293
Cashflow used in investing activities	(600)	(287)
Cashflow used in financing activities	209	(2,216)
Net cash inflow	1,634	(210)



Singapore's Leading Specialty Pharmaceutical and Consumer Healthcare Group



4 MAINTAINING DIVIDEND POLICY

S\$'000	Dividend	Yield ^(a)	Div / NP ^(b)
FY2019 ^(c)	1 cent	4.0%	46.0%
FY2018	0.55 cents	2.2%	30.5%


- (a) Yield is computed based on total dividends declared for the financial year divided by closing price of S\$0.25 @ 13 May 2020.
- (b) At least 30% of Net Profits Attributable to Shareholders in FY2018 & FY2019 intended to be distributed as dividends (IPO prospectus).
- (c) Reclass Final Dividends to Interim Dividends to facilitate earlier payment on 8 June 2020.

Commitment to maintain dividend policy to pay at least 30% of its net profits attributable to shareholders, subject to the Board's approval.



Singapore's Leading Specialty Pharmaceutical and Consumer Healthcare Group





Hyphens

Hyphens Pharma International Limited (SGX: 1J5)
 16 Tai Seng Street, Level 4, Singapore 534138
www.hyphensgroup.com

[in](#) Follow us on LinkedIn